UPDATE: Morgan Stanley Reiterates on AbbVie After Competitor's Schizophrenia Drug Fails
In a report published Tuesday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on AbbVie (NYSE: ABBV), but removed the $57.00 price target.
In the report, Morgan Stanley noted, “Targacept's (not covered) cognitive deficits in schizophrenia (CDS) drug, TC-5619, failed. This drug is similar to ABBV's ABT-126, which is being tested in Ph. IIb in both cognition in Alzheimer's and CDS. We have been estimating 20% odds of ABBV success in one of the two indications.”
AbbVie closed on Monday at $53.37.
Latest Ratings for ABBV
|Apr 2016||Societe Generale||Initiates Coverage on||Sell|
|Mar 2016||Deutsche Bank||Initiates Coverage on||Hold|
|Mar 2016||Goldman Sachs||Downgrades||Conviction Buy||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.